Antiviral susceptibility testing-flow cytometric analysis (AST-FCA) for the detection of cytomegalovirus drug resistance

被引:11
作者
Lipson, SM
Soni, M
Biondo, FX
Shepp, DH
Kaplan, MH
Sun, T
机构
[1] NYU,N SHORE UNIV HOSP,SCH MED,DEPT LABS,JANE & DAYTON BROWN & DAYTON T BROWN JR VIROL LAB,MANHASSET,NY 11030
[2] LONG ISL UNIV,DEPT HLTH SCI,BROOKVILLE,NY
关键词
D O I
10.1016/S0732-8893(97)00040-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Antiviral susceptibility testing-flow cytometric analysis (AST-FCA), an application of flow cytometry in conjunction with cell culture, was developed to identify susceptibility of cytomegalovirus (CMV) isolates to the antiviral drugs ganciclovir (GCV) and foscarnet (PFA). The viral isolates used in this study were obtained from peripheral blood of AIDS patients. Among GCV-susceptible strains, the mean 50% inhibitory concentration (IC50) using AST-FCA was 18 mu m (SI50 = 1.4). Among GCV resistant strains, the mean IC50 was 47 mu m (SI50 = 3.6). For PFA, the mean IC50 was 80 mu m (SI50 = 1.0) for susceptible strains. IC(50)s for strains resistant to PFA, showed no significant reduction of infectivity at the highest drug concentration (i.e., 200 mu m PFA) tested. Additional analyses confirmed the accuracy of AST-FCA by parallel testing using plaque reduction assay. AST-FCA is a novel, nonisotopic, and relatively simple to perform laboratory procedure for the identification of CMV drug-resistant strains. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 35 条
[1]  
CHUTKOWSKI C, 1995, GEN M AM SOC MICR, V20, P580
[2]   A METHOD FOR SIMULTANEOUS NUCLEAR IMMUNOFLUORESCENCE AND DNA CONTENT QUANTITATION USING MONOCLONAL-ANTIBODIES AND FLOW-CYTOMETRY [J].
CLEVENGER, CV ;
BAUER, KD ;
EPSTEIN, AL .
CYTOMETRY, 1985, 6 (03) :208-214
[3]   RAPID ANTIVIRAL DNA-DNA HYBRIDIZATION ASSAY FOR HUMAN CYTOMEGALOVIRUS [J].
DANKNER, WM ;
SCHOLL, D ;
STANAT, SC ;
MARTIN, M ;
SONKE, RL ;
SPECTOR, SA .
JOURNAL OF VIROLOGICAL METHODS, 1990, 28 (03) :293-298
[4]   FLOW CYTOMETRIC MEASUREMENT OF TOTAL DNA CONTENT AND INCORPORATED BROMODEOXYURIDINE [J].
DOLBEARE, F ;
GRATZNER, H ;
PALLAVICINI, MG ;
GRAY, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (18) :5573-5577
[5]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[6]  
ELMENDORF S, 1988, CYTOMETRY, V9, P254
[7]  
FIELD AK, 1994, CLIN MICROBIOL REV, V7, P1
[8]  
FRESHNEY RI, 1983, MANUAL BASIC TECHNIQ, P119
[9]   RAPID SCREENING FOR RESISTANCE TO GANCICLOVIR AND FOSCARNET OF PRIMARY ISOLATES OF HUMAN CYTOMEGALOVIRUS FROM CULTURE-POSITIVE BLOOD-SAMPLES [J].
GERNA, G ;
SARASINI, A ;
PERCIVALLE, E ;
ZAVATTONI, M ;
BALDANTI, F ;
REVELLO, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (03) :738-741
[10]  
JACOBSBERGER JW, 1986, CYTOMETRY, V7, P359